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Abstract
4-hydroxy-2-nonenal (HNE), a major non-saturated aldehyde product of lipid peroxidation, has 
been extensively studied as a signaling messenger. In these studies a wide range of HNE 
concentrations have been used, ranging from the unstressed plasma concentration to far beyond 
what would be found in actual pathophysiological condition. In addition, accumulating evidence 
suggest that signaling protein modification by HNE is specific with only those proteins with 
cysteine, histidine, and lysine residues located in certain sequence or environments adducted by 
HNE. HNE-signaling is further regulated through the turnover of HNE-signaling protein adducts 
through proteolytic process that involve proteasomes, lysosomes and autophagy. This review 
discusses the HNE concentrations and exposure modes used in signaling studies, the selectivity of 
the HNE-adduction site, and the turnover of signaling protein adducts.
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1. Introduction
4-hydroxy-2-nonenal (HNE) is a major α, β-unsaturated aldehyde derived from the 
decomposition of peroxidation products of omega-6 polyunsaturated fatty acids such as 
arachidonic acid and linoleic acid [1-5]. Besides being produced from the non-enzymatic 
peroxidation process, which has been well recognized and reviewed [3-6], HNE could also 
be generated enzymatically by cyclooxygenase-2 and lipoxygenase [7]. In addition, cells/
organisms may be exposed to HNE from food. HNE produced from dietary polyunsaturated 
fatty acids during food processing and storage [8, 9] could result in exposure of cells in the 
gestrointestinal tract and possibly enter circulation [10] (Fig.1). HNE features two functional 
groups, its carbonyl (−HC=O) and double bond (C2/C3, −C=C-) groups. This combination 
in conjugation makes HNE to react readily with bio-molecules including lipids, nucleic 
acids, and proteins, that can underlie oxidative damage [5]. Therefore, HNE has been widely 
recognized as both a marker of oxidative stress and the culprit in damage since its discovery 
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in the 1980s [3, 11-13]. Later, numerous studies have clearly shown that at physiological 
concentration HNE can act as a potent signaling messenger and be involved in the regulation 
of a variety of signaling pathways [14, 15], cellular processes and functions [16], through 
forming Michael and/or Schiff base adducts with signaling proteins including receptors, 
protein kinases, phosphatases, and transcription factors [13, 17].
Most studies on HNE-induced signaling are conducted in cell models and use a wide range 
of HNE doses. Some doses are far beyond the pathophysiological concentration of HNE and 
thus might be irrelevant to what happens in vivo. In addition, although the adduct reaction of 
HNE with cysteine, histidine, and lysine residues in proteins has been a focus of many 
studies, the selectivity and turnover of the HNE adducts of signaling proteins have not been 
summarized. In this review we intend to summarize the concentration of HNE in cells/
tissues and in vitro cell models used for cell signaling studies, and discuss the adduction 
sites of HNE within signaling proteins and the turnover after adduct formation.
2. Tissue concentration of HNE
2.1. Metabolism of HNE is cell/tissue dependent
HNE in the cells is rapidly degraded through several metabolic pathways including 
conjugation, reduction, and oxidation [18] (Fig.1). Conjugation with GSH, catalyzed by 
GST alpha isoforms especially GSTA4-4 [19], is the predominant pathway of HNE 
metabolism [18, 20-22] and responsible for at least 50% of HNE degradation in cells [21, 
23, 24]. HNE biotransformation in the other pathways leads to its oxidation to 4-hydroxy-2-
nonenoic acid (HNA) by aldehyde dehydrogenase [25, 26], or its reduction to 1, 4-
dihydroxy-2-nonene (DHN) by alcohol dehydrogenase [25] and aldo-keto reductase [27]. 
With reduction, HNE loses its ability to conjugate with proteins [28]. But even though the 
metabolic removal of HNE is efficient, 2-8% of the HNE in cells appears to form conjugates 
with proteins [18], and initiates signaling events.
HNE metabolism activities vary among tissues and cell types. Esterbauer et al. reported that 
rat liver exhibited the highest HNE metabolizing activity among liver, lung, brain, heart, 
kidney, and intestine. The last had less than 3% of the HNE metabolizing activity of liver, 
largely due to the lack of alcohol/aldehyde dehydrogenase activity in these tissues [25]. 
Consistently Zheng et al. also found that lung and brain in rat and mouse showed limited 
activity of HNE degradation by alcohol/aldehyde dehydrogenase compared to liver [28]. In 
addition, GST expression level and activity also vary with tissues [28]. Such variation in 
HNE metabolizing activity in different tissues means that HNE concentration may vary from 
tissue to tissue in vivo. HNE may have a relatively longer half-life in some tissues and could 
possibly result in higher and sustained HNE signaling in these tissues. On the other hand, a 
lower capacity for HNE metabolism may reflect a lower rate of lipid peroxidation and not 
result in a greater steady state level of free HNE. It is important to note that HNE 
metabolism may be altered during ontogenesis. For instance, Baradat et al. reported that 
compared to wild type cells, isogenic colon cells with a mutation on the adenomatous 
polyposis coli (APC) gene were more efficient in metabolizing HNE, due to a higher 
expression of HNE metabolizing enzymes [29]. Cancerous cells usually express relatively 
higher levels of antioxidants including GST [30] and thus potentially metabolize HNE at a 
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faster rate compared to normal cells. The relatively higher HNE metabolism capacity results 
in a shorter HNE half-life and less HNE toxicity in cancerous cells. On the other hand it 
suggests that more HNE production may be required to initiate a similar signaling response 
in cancerous cells. Regardless, the tissue-dependent differences in HNE metabolism may 
result in variation of HNE levels in different cells/tissues under physiological conditions.
2.2. Tissue concentration
Free HNE remains at very low level in plasma, cells, and tissues under physiological 
condition. In human plasma it is in the range of 0.28-0.68 μM, similar to that in the plasma 
of dogs and rats [1, 3, 31]. This persistent existence of free HNE [32] under normal 
physiological condition may reflect a homeostatic range between its production and 
metabolism [33]. Plasma HNE may mainly come from tissue cells including vascular 
endothelial cells and hepatocytes, and blood circulating cells such as lymphocyte and 
erythrocytes. HNE concentration in rat hepatocytes is in the range of 2.5 μM-3.8 μM, 
calculated from reports that HNE in rat hepatocytes is 0.86-1.3 nmol/108 cells and that a 
typical hepatocyte volume is 3.4×10−9 cm3 [34]. HNE in human blood monocytes is 3 times 
higher than in rat hepatocytes [3]. In other types of cells, HNE concentration is also much 
higher than its plasma level [5]. Since plasma HNE can reach most tissue cells, it is a fairly 
good indicator of the exogenous exposure level of cells throughout the body. Due to a tissue-
dependent HNE metabolizing capacity as discussed in the above, HNE concentration in 
different tissues may vary under physiological conditions.
Under conditions of oxidative stress and diseases, HNE level is significantly increased in 
plasma and tissues [3, 11-13]. In most of these studies, relative level of HNE-protein adduct, 
instead of free HNE concentration, is usually used as HNE marker, therefore most often only 
the relative comparison to healthy controls was available. Nonetheless, studies have 
demonstrated the increase of HNE in diseases and pathologies including Alzheimer disease 
[35-37], cancer [38], COPD [39], and cardiovascular diseases [40], as summarized in many 
excellent reviews ([16, 41]).
3. HNE doses used in cell signaling study
A wide range of doses has been used in studying HNE effects on cell signaling pathways. At 
concentration as low as 0.01 μM HNE was able to reduce endothelial cell junctional 
communication [42], activate G protein mediated signaling [43], and increase 
phosphoinositide-specific phospholipase C (PLC) activity and neutrophil migration [44]. On 
the other end, HNE level as high as 4 mM was used to investigate the effect of HNE on 
Ca2+-ATPase activity in rat liver plasma membrane [45]. The second highest concentration 
of HNE in the cell signaling literature was 500 μM, at which it inhibited Ca2+/Mg2+-ATPase 
activity on erythrocyte membrane [46] and Na+/K+-ATPase activity in rat striatal 
synaptosomes [47]. Analysis of literatures on HNE-mediated signaling showed that about 
17% of studies used 0.1-1 μM of HNE, which is in the physiological range, and that 29% of 
studies used 1-10 μM of HNE, which is in the range where pathology begins. Another 38% 
of studies were performed with a pathological level of HNE (10-50 μM). Overall most 
studies (84%) have used HNE in doses from 0.1-50 μM (Table 1).
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4. Exposure mode of HNE
Exogenous addition of an agent to cultured cells to mimic the in vivo exposure is always a 
challenge. In a review article Forman discussed the pros and cons of the use in cell model 
systems of exogenous application of nontoxic concentration of H2O2, a well-recognized 
second messenger in redox signaling [48]. HNE shares many aspects with H2O2 in terms of 
production and metabolism in signaling studies. Both are generated in vivo, with a higher 
loci concentration, and are degraded rapidly, producing a large gradient of concentration. 
Therefore the challenge of HNE exposure mode in signaling studies is similar as H2O2 -that 
is to mimic the physiologically relevant intracellular concentration at the loci of target. 
Indeed, the physiologically relevant target would need to be close to the site of HNE 
generation in the cell. But, few studies have examined the effect of endogenously generated 
HNE.
Most HNE signaling studies are performed in cell model systems and a variety of exposure 
modes have been applied. In this model, cells are usually cultured in medium containing 
10% or less fetal bovine serum (FBS), in some cases in FBS free medium or buffers. But in 
general, HNE is applied to cells through two modes; i.e., bolus one-time addition or repeated 
addition with intervals for several times. To reach its target signaling proteins, HNE has to 
escape the scavengers in serum-containing medium, the plasma membrane barrier, and the 
intracellular degradation system. Bolus-added HNE disappears rapidly in typical 10% FBS 
cell medium (80% disappears in 30 min) [49, 50], and thus HNE doses much higher than 
pathophysiologic level were usually used to cause effects in these studies. In other words, 
HNE reaching substrate-signaling molecules is obviously lower than the initial HNE 
concentration in the medium.
To mimic a stable HNE level for longer exposure time as is observed in vivo, many studies 
treat cells with a repeated additions of HNE [50-55]. Such an exposure mode was first used 
by Barrera et al. to investigate HNE effects on cell differentiation [56]. This group 
systematically measured and compared HNE concentration in cell medium after bolus or 
repeated addition of HNE [57]. When 10 μM HNE was added to RPMI medium with 10% 
FCS, 40% disappeared within 10 min; and after 30 min, HNE concentration in the medium 
was maintained at 4-6 μM for 1 h, indicating that HNE could be consumed by components 
in FCS. When 10 μM HNE was added to K562 cell suspension (106 cells/ml) in 10% FCS 
medium, it disappeared completely in 1h (undetected), with 78% having disappeared in the 
first 10 min (2.2 μM in medium). On the other hand, when 1 μM of HNE was added every 
45 min for 12 times into cell suspension in 10% FCS medium, HNE concentration in the 
medium remained stable at 1 μM [57]. Similarly, Laurora et al. also measured the HNE 
concentration in medium with the repeated addition of 1μM HNE to cells in 10% FBS 
medium every 45 min for 10 times, and found that HNE concentration in the medium could 
be maintained at around 2 μM [50].
Compared with bolus exposure, the advantages of this exposure mode are obvious. First, a 
stable HNE level is maintained for a longer period of time, more like the in vivo exposure 
situation; secondly, potential influence on cellular response resulting from serum-free 
condition could be avoided; and thirdly, a kinetic response could be detected during the 
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exposure period. In addition, accumulated HNE effects could be studied at lower HNE 
doses. However, since it takes time to reach a stable HNE level, it is inappropriate to 
investigate the initial targets and acute effects of HNE. In this case, bolus exposure seems 
more appropriate.
The biological effects of HNE are closely related to its concentration. At physiological 
levels, HNE is metabolized efficiently and at low intracellular concentration is maintained. 
Thus, its biological effects, if any, are barely observed. Under challenging conditions, where 
its concentration increases, HNE could act as signaling mediator and initiate various 
signaling cascades and regulate gene expression. At non-lethal but stressful concentrations, 
HNE induces processes including autophagy, senescence, and cell cycle arrest due to its 
pathologic modification of proteins and organelles. At lethal concentrations, HNE causes 
apoptosis or necrosis [58].
5. Selectivity of HNE modification on signaling proteins
HNE mediates cell signaling mainly through forming adducts with signaling protein 
molecules that results in change of protein activity. Cysteine, histidine, and lysine are the 
most active amino acids to react with HNE and proteins containing these residues could 
form Michael and/or Schiff base adducts with HNE [3, 5, 52, 53]. At the beginning Anti-
HNE adducts Ab and protein activity assay were used to assess HNE adduct formation and 
effects, and many HNE targeted proteins were identified with these approaches [59, 60]. The 
development of mass spectrometry (MS) and proteomic-based approach in the past decade 
has greatly enhanced the investigation of HNE-protein reaction. With the combination with 
other technologies such as Click chemistry, MS analysis becomes a power tool to profile 
HNE targets and spot specific modification sites [54-56].
Protein oxidation, including protein glutathionylation, nitration, and other types of 
electrophile–protein reactions, exhibits a significant degree of selectivity, which is assumed 
to be due to protein structure and location [61, 62]. Studies have identified many protein 
substrates of HNE conjugation, and revealed that HNE-protein reactions do not occur 
indiscriminately, instead similar to other protein oxidation reactions, exhibit a significant 
selectivity at several levels.
First, only proteins with residues of cysteine, histidine, or lysine are potential targets, 
proteins composed of residues other than these are far less likely to form covalent adducts 
with HNE, as evidenced in studies with model peptides [63] and proteins [64, 65] (Table 2). 
The covalent modification is mainly through Michael adduction while Schiff base adduction 
has been less detected.
Secondly, reactivity of the three amino acids residues with HNE is different. Among them, 
Cys is the most preferred, and the reactivity follows the order of Cys>His>Lys [63, 65]. 
However, this is not absolute and in some signaling proteins, His or Lys is preferred other 
than Cys, such as in signaling proteins of insulin [66], ERK1/2 [67], and serine/threonine 
kinase liver kinas B1 (LKB1) [68]. It should be noted that controversy exists on the HNE 
modification sites and reactivity even in the same protein. For example, Aldini et al. 
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investigated the reactivity of the nine residues of Cys, His, and Lys in human serum albumin 
[69] with HNE and found it followed an order of Cys-34 (Michael adduction) >Lys-199 
(Schiff's base adduction)>His-146 (Michael adduction) [65], while Szapacs et al. reported 
that the reactivity of these residues followed the order of His-242 > His-510 > His-67 > 
His-367 > His-247 [70]. Both studies used similar condition (recombinant pure HSA and 
similar reaction ratio of HSA: HNE) and mass spectrometry analysis. It seems that the 
selectivity difference is related with experiment conditions such as reaction concentration 
and time. Uchida et al. reported that HNE preferentially reacted with residues of Cys and 
Lys in GAPDH protein at concentration of less than 0.5 mM, while it reacted with all three 
residues at concentration of 2 mM [64]. Ishii et al. on the other hand, reported that the 
reaction of Cys, His, and Lys in GAPDH were time dependent. Both His-164 and Cys-281 
were very rapidly modified at 5 min, followed by Cys-244 at 15 min and His-327 and 
Lys-331 at 30 min, while the modification of Cys-149 at the catalytic center was not 
observed [71]. These controversies in reactivity and modification sites suggest that more 
studies are required to further elucidate the HNE alkylation sites of specific proteins, 
especially using models with similar condition as in vivo exposure, since most previous data 
were based on isolated pure protein and used HNE concentration that was not 
physiologically relevant. Another aspect about selectivity of HNE modification is that 
specific sequence motifs in proteins or secondary structure may be required for reaction of 
residues of Cys, His, or Lys with HNE. As observed in HSA [65, 72], Trx[73], human 
carboxylesterase1 [74] and other proteins that contain several residues of Cys, His, and Lys, 
only certain residues were able to adduct with HNE, and even these reactive residues 
exhibited different reactivity. The underlying mechanism of this selectivity remains largely 
unknown. Using computational modeling analysis, Aldini et al. showed that the reason why 
Cys374 of actin was the preferred site of HNE adduction was because of its significant 
accessible surface and substantial thiol acidity due to its particular microenvironment 
surrounding [75]. Szapacs et al. investigated the reactivity of HNE adduct residues and motif 
structure of HSA and found that the rate constants of His residues ranged over 4 orders of 
magnitude with the order of reactivity being His-242 > His-510 > His-67 > His-367 > 
His-247. The most reactive site H242 was located in a fatty acid- and drug-binding cavity of 
HSA. Further analysis of adduction kinetics together with HSA structure and pK(a) values 
of target residues suggested that location in the hydrophobic binding cavity and low 
predicted pK(a) of His-242 could account for its high reactivity toward HNE [70]. The 
relation between reactivity (selectivity) and motif sequence is further supported by a study 
from Doorn et al. [63], in which addition of a methionine to peptides significantly increased 
the reactivity of HNE reactive residues contained in them. Recently Yang et al. developed a 
chemoproteomics platform employing a novel, isotope-labeled Az-UV-biotin reagent and 
analyzed HNE alkylation sites on cysteine and histidine residues in about 400 proteins and 
revealed a characteristic sequence motif of CxxxK for HNE S-alkylation [76]. This powerful 
tool has a potential to expand the inventory of HNE modification sites of signaling proteins 
in complex biological samples. It is important for characterizing the interactions of HNE 
with redox sensitive cell signaling proteins and understanding how it may modulate their 
activities under either physiologic or disease conditions. With the combination of 
computation-based structure analysis, this technology would greatly further the 
understanding of the site selection of HNE covalent adduction in signaling proteins.
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Summarizing this section, it is important to understand that while the rate of adduct 
formation is much greater for Cys than the other two amino acids, the thiolate form of Cys 
(S−) is by far a better nucleophile than the thiol (SH) form. Nonetheless Cys, and 
particularly its thiolate form, are in lower abundance than either His or Lys in proteins. 
Furthermore, even with its far greater rate constant, Cys in its thiolate form is usually less 
accessible to adduction than are Lys or His that would tend to be at the protein/solvent 
interface.
HNE concentration would also affect which amino acids are modified. Aside from the 
accessibility issue for the Cys thiolate, at low concentrations of HNE, its modification would 
be greatly favored. When the concentration of HNE is high however, Cys adduction is still 
the favored reaction kinetically, but the likelihood of adduction to HNE with His and Lys 
increase. The bottom line is that while kinetics would largely favor Cys modification, 
geometry and relative abundance limit the modification of Cys, and that higher 
concentration of HNE makes Lys and His modification increase. Thus, it is important to 
determine the modifications for each individual target protein at realistic concentrations of 
HNE.
6. Stability and turnover of HNE-adducted signaling proteins
Protein modification by HNE is often associated with conformation change and loss of 
normal function. The accumulation of these non-native proteins could lead to harmful effects 
and is associated with pathologic changes. Therefore, HNE-adducted proteins are labeled as 
abnormal by cell protein quality control system, and are either repaired, removed, or 
accumulate as aggregated proteins in cells. Although the underlying mechanism of how cells 
discriminate between native and oxidized form of proteins including HNE-adducts remains 
to be further elucidated, a growing body of evidence suggests that oxidation of amino acid 
residues could cause protein unfolding and exposure of hydrophobic regions, which are 
normally buried in native form. The exposed hydrophobic patches could serve as signals for 
molecular chaperones and proteolytic system, and result in the refolding or degradation of 
target proteins [77]. A majority of studies indicate that oxidized proteins are mainly 
degraded by 20S proteasome [78-80], while there are also evidence suggest that ubiquitin-
dependent 26S proteasome, immunoproteasome [81, 82] and lysosome [77] are also 
involved in the degradation of oxidized proteins. Accumulating evidence suggests that 
autophagy may play a significant role in the degradation of heavily oxidized and aggregated 
proteins, which are poor substrate of proteasome system [83, 84]. It is generally considered 
that like other types of protein oxidation, HNE-modified proteins are degraded through 
proteasomes especially 20S proteasome. In addition, lysosome [85] and autophagy may also 
play a key role in the degradation and recycling of HNE-protein adducts [86, 87] (Fig.2). 
HNE-mediated signaling is usually transient and turned on and off in a time-dependent 
manner, and this is obviously related to the removal of bolus-added HNE and turnover of the 
signaling proteins initially adducted by HNE. Studies suggest that the appearance of HNE-
signaling protein adducts is substrate dependent, some occur within minutes while others 
occur at as late as several hours after HNE exposure. For instance, IκB-HNE adduct level in 
response to uniaxial cyclic stretch reached the highest level at 2 min [88] and HNE inhibited 
protein tyrosine phosphatase 1B (PTP1B ) activity in 5 min [89], while platelet derived 
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growth factor (PDGF)-HNE adduct was detected only after 2 h of HNE exposure [81]. This 
time difference in the occurrence of HNE-adducts may be related to the local HNE 
concentration. Rinna et al. investigated the response of SHP1 activity to different HNE 
concentrations and found that at 15μM, HNE inhibited SHP1 as early as in 5 min but at 5 
μM it needed 15 min to reach the same degree of SHP1 inhibition. In addition, reactivity and 
the location of the protein substrates may also play important roles in this time-dependent 
difference in adduct occurrence. To clarify the exact mechanism however, further studies are 
needed.
The stability or the turnover rate of HNE-signaling protein adducts also exhibit variation 
among target proteins. After formation, IκB-HNE adduct returned to basal level in 2 minutes 
[88], while HNE adducts with epithelial growth factor (EGFR) and insulin receptor substrate 
(IRS) remained detectable for at least 5 h [90, 91]. The presence of HNE-protein adduct 
however, seems to be due to accumulation other than resistance to degradation, as evidenced 
by both Dolinsky et al. [92] and Ma et al. [93] who observed that LKB1-HNE adduct level 
was higher in 1h of HNE exposure, but the total LKB1 protein was decreased. Consistently, 
Demozay et al. also found that even though the increase of HNE-IRS adducts level lasted for 
at least 6 h, the total IRS protein was significantly decreased [91]. However, it remains 
unclear whether other mechanisms such as increased secretion or inhibited translation are 
involved in the decrease in total proteins in the above cases. In contrast, Shearn et al. 
reported that AKT2-HNE level increased by 40 times in 2 h, and the total AKT2 protein did 
not change [94]. In summary, these limited data suggest that the turnover of HNE-signaling 
protein adducts may be substrate dependent. This point is supported by a recent study by 
Yang et al., who investigated the turnover of 398 HNE-protein adducts using a mass 
spectrometry-based quantitative chemoproteomics platform and found that the adduct 
turnover rates varied in a site-specific manner [76]. In contrast, studies found that HNE-
modified proteins usually decreased rapidly after removing HNE from medium and then 
remained at a stable level for longer time [85, 95]. For instance, Liu et al. reported that 
overall HNE protein adducts level decreased by 60% in 2 min of HNE exposure and then 
remained stable for at least 1h [87]. It remains unclear if proteasome was responsible for the 
rapid degradation of HNE-adducts, as it is hard to explain why the left 40% could be stable 
for 1 h. It is worthy to note that most HNE signaling studies are performed in cell models, 
which usually means short observation period and transient HNE exposure, compared to in 
vivo situation where HNE exposure persists and a possible balance between adduct 
formation and turnover could be reached. Further investigation of HNE-adduct turnover 
under these conditions would further our understanding of the mechanism of HNE-mediated 
signaling.
7. Conclusion and future studies
As a potent signaling mediator, HNE plays important roles in maintaining cellular 
homeostasis and in oxidative stress-implicated pathological changes [12, 96]. Most studies 
on HNE signaling in cultured cells were performed with HNE concentrations in the 
pathophysiologic range and whether HNE contributes to signaling effects at physiological 
concentration in vivo remains largely unknown. In addition, future studies on HNE signaling 
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should consider the exposure mode; i.e., bolus-addition and repeat exposure, which is 
closely related to the effective HNE doses and reaction time with targets.
Selectivity of HNE adduction reaction is an important topic in the research of HNE 
signaling, and is relatively less studied. Most previous studies on HNE target sites and 
selectivity assay were conducted on recombinant protein instead of living cells, in which 
different HNE concentration, protein structure, and microenvironment may exist. More 
studies with in vivo models, and with mass spectrometry based technologies [76], are needed 
before a clear and general rule in the selectivity of HNE target can be drawn
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Highlight
• A wide range of HNE concentrations have been used in studies of HNE 
signaling
• Bolus and repeated addition of HNE are useful, but do not exactly mimic 
physiologic exposure
• HNE conjugates with and modifies signaling proteins selectively
• HNE-signaling protein adducts are subsequently degraded
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Figure 1. 
HNE formation and pathway of metabolism. LOX, lipoxygenase; COX-2, 
cyclooxygenase-2; AR, aldo-keto reductase; GSTs, glutathione S-transferases; ALDH, 
aldehyde dehydrogenase; DHN, 1, 4-dihydroxy-2-nonene; GS-HNE, glutathione-HNE 
conjugate; HNE HNA, 4-hydroxy-2-nonenoic acid.
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Figure 2. 
Turnover of HNE-modified signaling molecules.
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Table 1
Usage of HNE concentration in signaling study
HNE concentration (μM) Percentage of studies (%)
≥500 1.7
100<HNE<500 1.7
50<HNE≤100 11.7
10<HNE≤50 38.0
1<HNE≤10 29.0
0.1≤HNE≤1 16.8
<0.1 1.1
Note. HNE concentration was calculated from the amount of HNE added and volume of medium or buffer and was based on 179 studies of HNE 
effect on signaling molecules/pathways from 1987-2015.
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Table 2
Modification of proteins by HNEa
Protein Adducted Residues Adducts Type Reactivity Detection method Reference
Insulin Two His and one Lys Michael adduct His>Lys HPLC, MS, and amino acid 
sequencing
[66]
GAPDH Cys, His, and Lys Michael, Schiff base 
adducts, and 
intramolecular and 
intermolecular crosslink
When [HNE]<0.5 mM, 
preferentially with Cys 
and Lys; when 
[HNE]=2 mM react 
with all three residues
HPLC [64]
β-lactoglobulin B Cysteine, histidine, 
and lysine.
Mainly Michael adducts Adducts containing 
from three to nine 
aldehyde molecules 
per molecule of protein
Electrospray ionization (ESI) 
MS
[97]
Protein kinas C (PKC) NA NA NA Anti-HNE adducts Ab [98]
Na (+)-K(+)-ATPase Cys and Lys NA NA Anti-HNE adducts Ab [99]
Erythrocyte membrane proteins NA NA Mainly with Cys at 
0-0.5 mM
Anti-HNE adducts Ab [100]
c-Jun N-terminal kinas (JNK) NA NA NA Anti-HNE histidine Ab [49]
FR-1 Cys298 Michael adduct NA ESI-MS [95]
Tau Lys NA NA Anti-HNE Lysine Ab [96]
Cytochrome c oxidase NA NA NA Anti HNE-histidine Ab [101]
IκB kinas (Frikke-Schmidt, 
#312)
NA NA NA Anti-HNE adducts Ab [102]
Bovine cathepsin B Cys29 and Michael adducts NA Pure protein, tandem MS and 
Anti-HNE adducts Ab
[103]
GAPDH His-164, Cys-244, 
Cys-281, His-327, 
and Lys-331 and 
revealed
Michael adducts His-164 and Cys-281 
were modified at 5 
min, followed by 
Cys-244 at 15 min and 
His-327 and Lys-331 
at 30 min, Cys-149 
modification was not 
observed
Pure protein, ESI liquid 
chromatography-mass 
spectrometry (ESI-LC-MS)
[71]
Carnosine NA Schiff base NA Anti-HNE adducts Ab [104]
Model peptides Cys, His and Lys are 
modified by 4HNE;
Michael adducts Cys>>His>Lys MALDI-TOF-MS [63]
Alpha 6/C2 subunit of 20s 
proteasome
NA NA NA MALDI-TOF MS [105]
Actin Cys374 NA Reactivity of Cys374 
is due to a significant 
accessible surface and 
substantial thiol acidity 
due to the particular 
microenvironment
Pure protein LC-ESI-MS/MS [75]
Protein disulfide isomerase 
(PDI)
Cys NA NA MS [102]
Carnosine Cys NA NA ESI-MS [106]
Epithelial growth factor receptor 
(EGFR)
NA NA NA Anti-HNE adducts Ab [107]
Human serum albumin [65] His-67, His-146, 
His-242, His-288, 
His-510, Lys-195, 
8 Michael Adducts 
(MA), 3 Schiff Base 
(SB)
Cys-34 (MA)>Lys-199 
(SB)>His-146 (MA)
LC-ESI-MS/MS [65]
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Protein Adducted Residues Adducts Type Reactivity Detection method Reference
Lys-199, Lys-525 
and Cys-34
Thioredoxin reductase Cys-496 NA NA MS [108]
Enolase 3b, aldolase and 
triosephosphate isomerase 1, 
creatine kinase, carbonic 
anyhdrase III, aconitase 2, 
dihydrolipoamide 
dehydrogenase, and electron 
transfer flavoprotein-beta
NA NA NA MS [106]
Type II collagen and MMP-13 NA Anti-HNE adducts Ab [109]
HSA 10 His and Lys 
residues
Michael Adducts H242 > H510 > H67 > 
H367 > H247
LC-MS-MS [70]
α-synuclein His-50 NA NA LC-MS/MS [110]
ADP/ATP translocase 1 Cys-256 Michael adducts NA MALDI-MS/MS [111]
Extracellular signal-regulated 
kinas ½ (ERK1/2)
His-178 NA NA LC-MS/MS [67]
Tubulin Cys-347, Cys-376, 
and Cys-303
Tubulin cross-links are 
Lys-dependent
NA LC-MS/MS [112]
HSA Cys-34 NA NA LC-ESI-MS/MS [113]
HSA Cys-34 and Lys-199 Cys-34 (MS) and 
Lys-199 (SB)
NA LC-ESI-MS/MS [72]
Akt NA NA NA Anti-HNE adducts Ab [114]
HSP70 and HSP90 NA NA NA Click chemistry and 
proteomics
[115]
Liver kinas B1 (LKB1) NA NA NA Anti-HNE adducts Ab [92]
Toll like receptor 4 (TLR4) Cys NA NA LC-MS/MS [116]
Trx Cys-73 and Cys-32 NA Cys-73 > Cys-32 NMR [73]
Type II collagen NA NA NA Anti-HNE adducts Ab [117]
Glutamate cysteine ligase: 
catalytic (GCLC) and modifier 
subunit (GCLM)
Cys-553 on GCLC 
and Cys-35 on 
GCLM
NA NA Pure protein, MALDI-TOF [118]
Human carboxylesterase1 Lys-105 and Cys-389 Only Lys-105 adducted MS [74]
SIRT3 deacetylase Cys-280 NA NA MS/MS [119]
AKT2 His-196, His-267, 
and Cys-311 of rat 
Akt2
Michael Adducts NA Anti-HNE adducts Ab and 
MALDI-TOF
[94]
Phosphatase and tensin homolog 
(PTEN)
NA Single Michael adduct NA Anti-HNE adducts Ab and 
MALDI-TOF/TOF
[120]
EGFR NA NA NA Anti-HNE adducts Ab [121]
LKB1 Lys-97 NA NA Anti-HNE adducts Ab [68]
IκBα NA NA NA Anti-HNE adducts Ab [122]
PKC NA NA NA Anti-HNE adducts Ab [123]
Liver fatty acid-binding protein 
(L-FABP)
Lys-57 and Cys-69 
on apo and Lys-6, 
Lys-31, His-43, 
Lys-46, Lys-57 and 
Cys-69) on holo 
protein
NA NA Pure protein, MALDI-
TOF/TOF MS
[124]
Arch Biochem Biophys. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Zhang and Forman Page 23
Protein Adducted Residues Adducts Type Reactivity Detection method Reference
Peptidyl-prolyl cis/trans-
isomerase A1 (Pin1)
His-157 and Cys-113 Michael adducts Cys-113 is the primary MALDI-TOF/TOF MS [125]
Mitochondrial aconitase (ACO2) Cys Michael adducts The most reactive sites 
were Cys-358, 
Cys-421, Cys-424, 
Cys-99 and Cys-565
MS [126]
Angiotensin II (Ang II) NA NA NA Anti-HNE adducts Ab [127]
GRP78 Lys and His NA Marked propensity for 
Lys and His adduction 
within the ATPase 
domain
MS [128]
Lactate dehydrogenase (LDH) His-68, Cys-164, 
Cys-186, and 
Cys-294
Michael adducts NA Purified protein, MS [129]
5′ AMP protein kinase (AMPK) Cys-130, Cys-174, 
Cys-227, and 
Cys-304 on AMPKα 
and Cys-225 on 
AMPKβ
Michael adducts NA Pure protein, MS [130]
Protein kinase A Cys-199 NA NA MS [131]
Src Cys-248 NA NA LC-MS/MS [132]
398 proteins 386 Cys sites and 12 
His sites
Michael adducts NA MS [76]
Cyclin-dependent kinas 2 
(CDK2)
NA NA NA MS [133]
Apoptosis inducing factor 
(AIFm2)
His-174 NA NA MS [134]
Note. NA, not available; MS, mass spectrometry.
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